Myelodysplastic Syndromes
Results reported from Dacogen phase III study in myelodysplastic syndromes
Published in Cancer Weekly, April 27th, 2004
The study enrolled 170 patients at 22 North American sites, with 89 randomized to Dacogen plus supportive care and 81 randomized to supportive care only.
Supportive care included antibiotics, growth factors, and/or transfusions. The data analysis was performed after 92 patients reached the primary endpoint of either progression to acute myelogenous leukemia (AML) or death.
Patients randomized to the Dacogen arm had an increased time to progression to AML or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-04-27)
More Articles from Cancer Weekly
- Cancer Therapy
Early, high-dose chemotherapy with HPCS effective for poor prognosis GCT - Cancer Therapy
INO-1001, novel inhibitor of PARP, enhances radiation sensitivity - Genomics
Distinct mechanisms lead to HPRT gene mutations in leukemic cells - Liver Cancer
Liver adenomatosis associated with diabetes phenotype - Liver Cancer
Researchers discover gene that causes liver cancer in animals - Abdominal Cancers
Selective radiation therapy to abdomen can preserve fertility - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
